LeserbriefKommentar
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply
JAMA · 2023
DOI: 10.1001/jama.2022.22649 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Mark G Lebwohl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Phosphodiesterase 4 InhibitorsPsoriasisHumansAdministration, CutaneousAminopyridinesBenzamidesChronic DiseaseCyclopropanesDouble-Blind MethodSeverity of Illness IndexSkin CreamTreatment Outcome
Substanzen
AminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 InhibitorsRoflumilast
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, New York.
- SkiN Centre for Dermatology, Peterborough, Ontario, Canada.
- McGovern Medical School at UTHealth Houston, Houston, Texas.
Zitieren
APA
Lebwohl, M. G., Hebert, A. A., & Gooderham, M. J. (2023). Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply. JAMA. https://doi.org/10.1001/jama.2022.22649
Vancouver
Lebwohl MG, Hebert AA, Gooderham MJ. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply. JAMA. 2023. doi:10.1001/jama.2022.22649
BibTeX
@article{Lebwohl2023,
author = {Lebwohl, Mark G and Hebert, Adelaide A and Gooderham, Melinda J},
title = {Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2022.22649}
}
EUVIMED